Why Are Effective, Inexpensive, Generic Outpatient COVID-19 Treatments Being Suppressed?
In December, I wrote about a Senate Homeland Security and Governmental Affairs Committee hearing focused on testimony about potential early and outpatient treatments for COVID-19. A group of doctors detailed their research on ivermectin, a generic anti-parasitic drug:
The medication being discussed in this hearing is ivermectin. It has not been studied as much as HCQ, but the results to date are encouraging
. The witnesses have studies covering over 4,000 patients in various settings but cannot obtain a review through the NIH. They asked for the committee’s assistance with this and noted that funding for additional studies is not readily available. Money to study the efficacy of current generic medications in new applications is difficult to obtain. That is a tragic fact, as these medications are less expensive and more readily available.
During the hearing, one of the physicians stated that with the results the researchers have seen to date, he would consider it malpractice not to provide this medication early in a COVID-19 infection. A website that tracks medications studies in COVID-19 has summarized a meta-analysis of the research to date for ivermectin:
Check out the trial data here.